In the work by Zhong et al. a subgroup analysis of studies using multivariable analyses, BRCA1 mutation carriers only had borderline worse overall survival (HR = 1.40, p = 0.05) and also another recent review of the literature and meta-analysis did not find worse breast cancer survival in the adjuvant setting for BRCA1/2 mutation carriers [25]. This evidence concerns the gene BRCA1 and breast carcinoma.